Elephantiasis nostras verrucosa: beneficial effect of oral etretinate therapy.
Elephantiasis nostras verrucosa is characterized by chronic secondary, non-filarial lymphoedema due to recurrent lymphangitis, dermal fibrosis, and epidermal changes consisting of hyperkeratotic, verrucous and papillomatous lesions. Histologically, there is pseudoepitheliomatous hyperplasia. Therapeutic efforts should aim to reduce lymph stasis, which will also lead to improvement of the cutaneous changes. In this study, rapid disappearance of the hyperkeratotic and verrucous lesions, remarkable flattening of the papillomatous nodules and improvement of lymphoedema occurred in three obese patients treated with etretinate in an initial dose of 0.6-0.75 mg/kg/day for 4-6 weeks. Monitoring of plasma concentrations of etretinate, acitretin and 13-cis-acitretin by HPLC revealed sufficient short-time absorption (4 h) and bioavailability of the drug (30 days; two out of three patients). Long-term maintenance therapy in one patient produced a remarkable improvement in the lymphoedema; another patient relapsed after discontinuation of the etretinate and responded again after this was reintroduced. In the third patient treatment was withdrawn because of an increase in triglycerides, but improvement persisted 6 months later. The clinical side-effects of oral retinoid therapy were moderate and well tolerated.
Zouboulis
C C
CC
Department of Dermatology, University Medical Center Steglitz, Free University of Berlin, Germany.
Biczó
S
S
Gollnick
H
H
Reupke
H J
HJ
Rinck
G
G
Szabó
M
M
Fekete
J
J
Orfanos
C E
CE
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D004604:Elephantiasis / Q000188:drug therapy* / Q000473:pathology; D005050:Etretinate / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007868:Leg Dermatoses / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology
D005050:Etretinate